Ning Jin

Associate Proffessor

Ohio State University
Country flagUnited States
ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (26)

The incidence of colorectal cancer in young adults (age of diagnosis Significance: We investigated whether environmentally driven factors contribute to EOCRC. We observed accelerated epigenetic aging in EOCRC and epigenetic changes associated with chronic inflammation. Tumor immune cell abundances correlated more strongly with microbes in EOCRC than in AOCRC. These data suggest a dysregulation of the immune response in EOCRC, driving chronic inflammation and tissue aging.

Year:

2025

Relationship between microbes and immune cell composition. A, All microbe-genus level abundances (columns) correlated to the deconvolved immune cell abundances (rows), with the strength of the association and its direction indicated by color in the TCGA (top row) and ORIEN (bottom row) datasets. Spearman correlations between the deconvolved abundance of ( B ) activated mast cells or ( C ) neutrophils and microbes in both the TCGA and ORIEN datasets. Concordant associations (significant in both and in the same direction) are shown in green, with select taxa labeled. There were no microbes significantly anticorrelated with activated mast cells or neutrophils.

Year:

2025

Accelerated aging with epigenetic signatures in EOCRC. A, Heatmap was drawn with samples (patients) in the row and CpG sites (probes) in the column. The DNAm values range from 0.0 (completely unmethylated, blue) to 1.0 (completely methylated, red). B, The volcano plot demonstrated differential methylated sites (expressed as β values) between EOCRC and AOCRC groups. △β for each CpG site is defined as β value of (EOCRC – AOCRC). FDR-adjusted P P value P value C, Box plot showed the mean β value of patients with EOCRC and AOCRC was 0.46 ± 0.028 and 0.47 ± 0.027 ( P value = 0.13, two-sample t test), respectively. D, Box plots demonstrated the accelerated aging in EOCRC. The DNAm age acceleration (Δ = methylation age − chronologic age) in EOCRC and AOCRC for all samples is shown. The Δ EOCRC predicted by Horvath, Hannum, and PhenoAge models was 2.1, 18.4, and 32.8 years, respectively. The Δ AOCRC predicted by Horvath, Hannum, and PhenoAge was −14.2, 3.4, and 27.1 years, respectively, with P values of 7.89E−12, 1.48E−08, and 0.17, respectively.

Year:

2025

Intratumoral microbes do not show consistent differences in EOCRC. A, Venn diagram demonstrated partial overlap in microbes among three datasets. The abundances of observed genera that passed stringent quality and contamination filters are shown (ORIEN, n = 353 genera; TCGA, n = 357 genera; and 16S, n = 30 genera), with the best agreement between the two RNA-seq datasets. B, The Bray–Curtis dissimilarity plot showed that RNA-seq–derived microbes were most similar to 16S microbes from the same tumor (paired) and least similar to microbes from adjacent normal tissue from another person (unpaired). C, The comparison of the relative abundance of microbes between the 16S-based dataset and the RNA-seq–based datasets (ORIEN and TCGA). D–F, Volcano plots showed no consistent differences in microbes from RNA-seq–based (TCGA, ORIEN) or 16S-based datasets. No microbes passed the significance threshold in EOCRC. G–I, Effect sizes of the most significant taxa across the three analyses showed no similarities in the AOCRC-enriched microbes.

Year:

2025

Methylation signature validation through GE profiles in EOCRC. A, Integration of the differentially methylated sites with paired RNA-seq showed genes that vary in methylation and transcription. The threshold for the FDR-adjusted P values for differences is 0.05 (FDR P value ≤ 0.05). Highlighted genes in orange indicate significant hypomethylation and expression. B, The canonical pathways involved with DMGs in EOCRC have an FDR-adjusted P value C and D, Bubble chart of pathways based on DEGs in EOCRC from TCGA and ORIEN, highlighting those predicted by methylation alone. The color of the pathways is based on their z -score, and the size of the bubble is correlated with the number of genes from the dataset that overlap each pathway. E, Summary of the analyses to validate the differential methylation, with those supported by all three datasets indicated within the box.

Year:

2025

Purpose: Colorectal cancer is the second leading cause of cancer-related mortality in the United States. Chemotherapies based on 5-fluorouracil (5-FU), when combined with targeted agents, remain the standard of care for patients with metastatic or locally advanced disease. New treatment strategies are needed for patients with metastatic colorectal cancer with microsatellite stable disease. Preclinical studies have shown that riluzole, an oral medicine for amyotrophic lateral sclerosis, inhibits glutamate release and synergizes with 5-fluorouracil to reduce cell viability in colorectal cancer cell lines. Patients and Methods: In this single-arm, phase I trial of riluzole in combination with mFOLFOX6/bevacizumab for patients with metastatic colorectal cancer, the riluzole dose started at 50 mg twice daily, escalating to 100 mg twice daily or de-escalating to 50 mg once daily. Patients received riluzole for 16 weeks in combination with mFOLFOX6/bevacizumab for eight cycles. Patients then either continued mFOLFOX6/bevacizumab or switched therapies. Results: Twelve of the 14 patients enrolled were evaluable. All patients had previously received FOLFOX, and five patients (41.7%) showed disease resistance to it. Two patients obtained partial responses, nine had stable disease, and one had progressive disease. The objective response rate was 16.7%, and the disease control rate was 91.7%. The median duration of response was 4.9 months (95% confidence interval, 1.6–9.8). Median progression-free survival and overall survival were 4.89 and 12.98 months, respectively. Conclusions: Our study showed that riluzole plus mFOLFOX6/bevacizumab is well tolerated in patients with metastatic colorectal cancer and may have clinical activity in patients whose disease is resistant to FOLFOX.

Year:

2025

Background: The incidence of colorectal cancer (CRC) in young adults (age of diagnosis < 50 years old) has been rapidly increasing. Although ~20% of early-onset (EO) CRC cases are due to germline mutations, the etiology of the majority of EOCRC cases remains poorly understood. Non-genetic factors such as environmental exposure and lifestyle changes are likely to have a direct link to the increased incidence of sporadic EOCRC. We hypothesize that such factors may be observable as differences in the EOCRC epigenome, microbiome and immunome. We sought to address this by comparing differences in DNA methylation from the cohort of colorectal cancer patients in The Cancer Genome Atlas (TCGA). Further, we carefully identified intra-tumoral microbes from TCGA and two other datasets and then related the microbes to EOCRC status and deconvolved immune cell abundances. We found that DNA methylation (DNAm) age acceleration by12 years when compared with average-onset CRC (AOCRC) patients. Differentially methylated sites associated with genes are related to CREB signaling in neurons, G protein coupled receptor signaling, phagosome formation and S100 family signaling. These differences were validated in the gene expression from TCGA and a second, larger real-world dataset from the Oncology Research Information Exchange Network (ORIEN). However, no consistent differences were observed in the intra-tumor microbes between EOCRC and AOCRC. Interestingly, the most abundant microbes interacted with the immune systems differently between the EOCRC and AOCRC tumors, characterized by more, larger, positive correlations in EOCRC. These data suggest epigenetic modulation and accelerated aging may play a key role in the development of EOCRC.

Year:

2025

Colorectal cancer is the second leading cause of cancer mortality in the United States. Although immune checkpoint blockade therapies including anti-PD-1/PD-L1 have been successful in treating a subset of patients with colorectal cancer, the response rates remain low. We have found that riluzole, a well-tolerated FDA-approved oral medicine for treating amyotrophic lateral sclerosis, increased intratumoral CD8 + T cells and suppressed tumor growth of colon cancer cells in syngeneic immune–competent mice. Riluzole-mediated tumor suppression was dependent on the presence of CD8 + T cells. Riluzole activates the cytosolic DNA sensing cyclic GMP-AMP synthase (cGAS)/stimulator of interferon genes (STING) pathway in colon cancer cells, resulting in increased expression of IFNβ and IFNβ-regulated genes including CXCL10. Inhibition of ataxia telangiectasia mutated (ATM), but not ATM-related, resulted in a synergistic increase in IFNβ expression, suggesting that riluzole induces ATM-mediated damage response that contributes to cGAS/STING activation. Depletion of cGAS or STING significantly attenuated riluzole-induced expression of IFNβ and CXCL10 as well as increase of intratumoral CD8 + T cells and suppression of tumor growth. These results indicate that riluzole-mediated tumor infiltration of CD8 + T cells and attenuation of tumor growth is dependent on tumor cell–intrinsic STING activation. To determine whether riluzole treatment primes the tumor microenvironment for immune checkpoint modulation, riluzole was combined with anti-PD-1 treatment. This combination showed greater efficacy than either single agent and strongly suppressed tumor growth in vivo . Taken together, our studies indicate that riluzole activates cGAS/STING-mediated innate immune responses, which might be exploited to sensitize colorectal tumors to anti-PD-1/PD-L1 therapies.

Year:

2025

Emerging evidence supports the important role of the tumor microbiome in oncogenesis, cancer immune phenotype, cancer progression, and treatment outcomes in many malignancies. In this study, we investigated the metastatic melanoma tumor microbiome and its potential roles in association with clinical outcomes, such as survival, in patients with metastatic disease treated with immune checkpoint inhibitors (ICI). Baseline tumor samples were collected from 71 patients with metastatic melanoma before treatment with ICIs. Bulk RNA sequencing (RNA-seq) was conducted on the formalin-fixed, paraffin-embedded and fresh frozen tumor samples. Durable clinical benefit (primary clinical endpoint) following ICIs was defined as overall survival ≥24 months and no change to the primary drug regimen (responders). We processed RNA-seq reads to carefully identify exogenous sequences using the {exotic} tool. The age of the 71 patients with metastatic melanoma ranged from 24 to 83 years, 59% were male, and 55% survived >24 months following the initiation of ICI treatment. Exogenous taxa were identified in the tumor RNA-seq, including bacteria, fungi, and viruses. We found differences in gene expression and microbe abundances in immunotherapy-responsive versus nonresponsive tumors. Responders showed significant enrichment of bacteriophages in the phylum Uroviricota, and nonresponders showed enrichment of several bacteria, including Campylobacter jejuni . These microbes correlated with immune-related gene expression signatures. Finally, we found that models for predicting prolonged survival with immunotherapy using both microbe abundances and gene expression outperformed models using either dataset alone. Our findings warrant further investigation and potentially support therapeutic strategies to modify the tumor microbiome in order to improve treatment outcomes with ICIs. Significance: We analyzed the tumor microbiome and interactions with genes and pathways in metastatic melanoma treated with immunotherapy and identified several microbes associated with immunotherapy response and immune-related gene expression signatures. Machine learning models that combined microbe abundances and gene expression outperformed models using either dataset alone in predicting immunotherapy responses.

Year:

2025

Prediction of random forest model combining microbe abundance and gene signatures. Balanced accuracies achieved by the microbe abundance, gene expression, and combined models for each of the three datasets.

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Collaborators (33)

Eric Singer

Professor

The Ohio State University Wexner Medical Center

UNITED STATES
View details

Jiangjiang Zhu

Ohio State University

UNITED STATES
View details

Wayne Miles

Assistant Professor

Ohio State University

UNITED STATES
View details

Chunjie Li

Assistant Professor

Washington University in St. Louis

UNITED STATES
View details

Gregory Riedlinger

Rutgers Cancer Institute of New Jersey

UNITED STATES
View details

Nicholas Denko

Professor

Ohio State University

UNITED STATES
View details

Arjun Mittra

Assistant Professor

The Ohio State University Comprehensive Cancer Center

UNITED STATES
View details

Aik Choon Tan

Senior Director of Data Science

Huntsman Cancer Institute

UNITED STATES
View details

Mitch Phelps

Ohio State University

UNITED STATES
View details

Lai Wei

Research Assistant Professor

Ohio State University

UNITED STATES
View details

Ashish Manne

The Ohio State University Comprehensive Cancer Center

UNITED STATES
View details

Martin D. McCarter

Professor

University of Colorado Anschutz Medical Campus

UNITED STATES
View details

Carlos HF Chan

Emory University

UNITED STATES
View details

Jing J. Wang

Ohio State University

UNITED STATES
View details

Sameek Roychowdhury

Ohio State University

UNITED STATES
View details

Anne Noonan

Professor

The Ohio State University Comprehensive Cancer Center

UNITED STATES
View details

Matthew Kalady

Professor

Ohio State University

UNITED STATES
View details

John D. Carpten

City of Hope Comprehensive Cancer Center

UNITED STATES
View details

Alexandra Ikeguchi

Associate Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Rebecca Dodd

Assistant Professor

The University of Iowa

UNITED STATES
View details

Gabriel Tinoco

Associate Professor of Medicine

Ohio State University

UNITED STATES
View details

Anjun Ma

Assistant Professor

Ohio State University

UNITED STATES
View details

Sheetal Hardikar

University of Utah

UNITED STATES
View details

Qin Ma

Vice Chair for Research

Ohio State University

UNITED STATES
View details

Yousef Zakharia

Mayo Clinic Arizona

UNITED STATES
View details

Misbah Khan

Northwestern University

UNITED STATES
View details

Dan Spakowicz

Assistant Professor

The Ohio State University Comprehensive Cancer Center

UNITED STATES
View details

Daniel W. Rosenberg

University of Connecticut Health Center

UNITED STATES
View details

Xiaokui Mo

Research Scientist

Ohio State University

UNITED STATES
View details

Ahmad Tarhini

Senior Member, Professor

H Lee Moffitt Cancer Center and Research Institute

UNITED STATES
View details

Griffin Caryotakis

Huntsman Cancer Institute

UNITED STATES
View details

Caroline Dravillas

Ohio State University

UNITED STATES
View details

YunZhou Liu

Ohio State University

UNITED STATES
View details